| Autor: |
Cheung NC; 1Florida Agricultural and Mechanical University, Tallahassee, Florida., Noviasky JA; 2Upstate Community Hospital, Department of Pharmacy, Syracuse, New York., Ulen KR; 3Upstate Community Hospital, Syracuse, New York., Brangman SA; 4SUNY Upstate Medical University Department of Geriatrics, Syracuse, New York. |
| Jazyk: |
angličtina |
| Zdroj: |
The Senior care pharmacist [Sr Care Pharm] 2022 Jul 01; Vol. 37 (7), pp. 284-292. |
| DOI: |
10.4140/TCP.n.2022.284 |
| Abstrakt: |
Objectives To evaluate the efficacy and safety of megestrol for off-label use in older patients with weight loss. Design Retrospective, nonblinded cohort study. Setting Upstate University Hospital is a 420-bed facility and academic medical center with a level 1 trauma center. Upstate Community Hospital is a 314-bed acute care/hospital/ambulatory care center and long-term care hospital that also provides teaching services. Participants Patients 65 years of age and older without malignancy or acquired immunodeficiency syndrome who were initiated and continued megestrol therapy at the Upstate University hospitals for at least two weeks were included. Of the 1,290 patients initially screened, 16 patients on megestrol were evaluated. An age- and gender-matched control group of 16 patients was utilized for comparison of changes in weight and other variables. Interventions Patients in the megestrol group have received daily doses of megestrol between 160 mg to 800 mg for an average duration of 19 days. Patients in the control group had no history or current use of megestrol utilization. Main Outcome Measurements The primary outcome was an increase in weight. Secondary outcome measures included albumin and thromboembolic events. Changes in weight and albumin were also compared with the control group. Results At a mean duration of 19 days, there was no significant difference in weight gain (0.95 kg, OR = 1.33 [95% CI -1.615-3.527]). Albumin decreased by (0.4 g/dL OR = 0.916 [95% CI 0.12-0.78]) and none of the patients developed a thromboembolic event. Conclusion In older hospitalized patients, megestrol did not increase weight, and did not improve albumin. No thromboembolic events were observed, but this may be because of a limited duration of observation of therapy and the routine use of anticoagulation prophylaxis in the inpatient setting. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
